101. Component-Resolved Diagnosis for Endotyping Patients with Chronic Rhinosinusitis with Nasal Polyps.
- Author
-
Puxeddu I, Petrelli F, Cristofani-Mencacci L, Scarano M, Latorre M, De Rosa A, Dallan I, Manca ML, Berrettini S, Migliorini P, and Seccia V
- Subjects
- Adult, Allergens, Chronic Disease, Humans, Inflammation, Quality of Life, Asthma diagnosis, Asthma epidemiology, Hypersensitivity epidemiology, Hypersensitivity, Immediate, Nasal Polyps complications, Nasal Polyps diagnosis, Nasal Polyps epidemiology, Sinusitis diagnosis, Sinusitis epidemiology
- Abstract
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a predominantly type 2 inflammation-mediated disease of the nasal mucosa and paranasal sinuses that often coexists with asthma. The role of atopy in the development and severity of CRSwNP is still a controversial issue., Objective: The aim of our study was to propose a systematic allergy workup to identify atopic patients in the context of CRSwNP and to characterize their allergen sensitization profile (sources/molecules)., Methods: Patients with a diagnosis of CRSwNP (n = 97) were studied in the otorhinolaryngologist and allergy settings. Demographic and clinical data were collected for each patient. Different allergen sensitization profiles (sources/molecules) were evaluated in atopic CRSwNP patients by using component-resolved diagnosis (CRD)., Results: In our cohort of patients, the CRSwNP was frequently diagnosed during adulthood with significant impact on health-related quality of life. Asthma and atopy were the most common comorbidities with a prevalence of asthma in the atopic group. In CRSwNP patients sensitized to grass pollens and/or to house dust mites, the CRD analysis revealed a prevalence of sensitization to species-specific allergens of Phleum pratense (Phl p1, Phl p2, and Phl p5) or Dermatophagoides pteronyssinus (Der p1 and Der p2) rather than to cross-reactive ones., Conclusion: To define the allergen sensitization profile in atopic CRSwNP patients by CRD, it may be useful to better characterize type 2 inflammation, thus providing a personalized endotype-driven treatment., (© 2022 S. Karger AG, Basel.)
- Published
- 2022
- Full Text
- View/download PDF